DA-EPOCH regimen: Difference between revisions

	WikiDoc Resources for DA-EPOCH regimen
Articles
Most recent articles on DA-EPOCH regimen Most cited articles on DA-EPOCH regimen Review articles on DA-EPOCH regimen Articles on DA-EPOCH regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on DA-EPOCH regimen Images of DA-EPOCH regimen Photos of DA-EPOCH regimen Podcasts & MP3s on DA-EPOCH regimen Videos on DA-EPOCH regimen
Evidence Based Medicine
Cochrane Collaboration on DA-EPOCH regimen Bandolier on DA-EPOCH regimen TRIP on DA-EPOCH regimen
Clinical Trials
Ongoing Trials on DA-EPOCH regimen at Clinical Trials.gov Trial results on DA-EPOCH regimen Clinical Trials on DA-EPOCH regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on DA-EPOCH regimen NICE Guidance on DA-EPOCH regimen NHS PRODIGY Guidance FDA on DA-EPOCH regimen CDC on DA-EPOCH regimen
Books
Books on DA-EPOCH regimen
News
DA-EPOCH regimen in the news Be alerted to news on DA-EPOCH regimen News trends on DA-EPOCH regimen
Commentary
Blogs on DA-EPOCH regimen
Definitions
Definitions of DA-EPOCH regimen
Patient Resources / Community
Patient resources on DA-EPOCH regimen Discussion groups on DA-EPOCH regimen Patient Handouts on DA-EPOCH regimen Directions to Hospitals Treating DA-EPOCH regimen Risk calculators and risk factors for DA-EPOCH regimen
Healthcare Provider Resources
Symptoms of DA-EPOCH regimen Causes & Risk Factors for DA-EPOCH regimen Diagnostic studies for DA-EPOCH regimen Treatment of DA-EPOCH regimen
Continuing Medical Education (CME)
CME Programs on DA-EPOCH regimen
International
DA-EPOCH regimen en Espanol DA-EPOCH regimen en Francais
Business
DA-EPOCH regimen in the Marketplace Patents on DA-EPOCH regimen
Experimental / Informatics
List of terms related to DA-EPOCH regimen

VisualWikitext

Revision as of 15:54, 12 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:DA-EPOCH; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH; EPOCH Regimen; EPOCH regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen

Overview

DA-EPOCH regimen refers to a chemotherapy regimen consisting of Dose-adjusted etoposide, prednisone, vincristine (Oncovin) ,Cyclophosphamide and doxorubicin (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.^[1]

Regimen

EEtoposide

PPrednisone

Ovincristine (Oncovin)

CCyclophosphamide

Hdoxorubicin (hydroxydaunorubicin hycrochloride)

Indications

Primary mediastinal(thymic)B-cell lymphoma^[2]

References

↑ "NCI Thesaurus".
↑ Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.

[1] "NCI Thesaurus".

[pmid25596693-2] Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.

[1]

[2]

@@ Line 6: / Line 6: @@
 ==Overview==
 {{PAGENAME}} refers to  a chemotherapy regimen consisting of Dose-adjusted [[etoposide]], [[prednisone]], [[vincristine|vincristine (Oncovin)]] ,[[Cyclophosphamide]] and [[doxorubicin (hydroxydaunorubicin hycrochloride)]], which may be used in combination with [[rituximab]] (R-EPOCH) for the treatment of various aggressive B cell and T cell [[non-Hodgkin lymphomas]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url =  http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63779 }}</ref>
 ==Regimen==
+{{chemo|E|Etoposide}}
-{{chemo|E|Etoposide}}
 {{chemo|P|Prednisone}}
 {{chemo|O|vincristine (Oncovin)}}
 {{chemo|C|Cyclophosphamide}}